SCHEMBL10275889

SCHEMBL10275889

CCOC(=O)c1c(-c2ccc(C(F)(F)F)cc2)[nH]c2c(-c3ccc(F)cc3F)c(-c3ccccc3)nn2c1=O

nearest known ligand 0.41

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
PLAT P00750 1/20 0.41
MAT2A P31153 2/20 0.40
DHODH Q02127 1/20 0.39
SLC34A1 Q06495 1/20 0.39
TP53 P04637 1/20 0.39
ALOX5 P09917 1/20 0.39
MEN1 O00255 2/20 0.38
KMT2A Q03164 2/20 0.38
ALDH1A1 P00352 4/20 0.37
KDM4E B2RXH2 2/20 0.37
HPGD P15428 2/20 0.37
L3MBTL1 Q9Y468 1/20 0.37
GAA P10253 1/20 0.37
SMN1; SMN2 Q16637 1/20 0.37
GCGR P47871 1/20 0.37
MAPK14 Q16539 1/20 0.37
NPSR1 Q6W5P4 1/20 0.37
PDE4A P27815 1/20 0.37
PDE4B Q07343 1/20 0.37
PDE4C Q08493 1/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL10276495 0.89 ALDH1A1 (0.44) PLATSLC34A1ALOX5MEN1KMT2A
SCHEMBL10275336 0.88 ALDH1A1 (0.45) PLATMAT2ASLC34A1TP53MEN1
SCHEMBL10275932 0.88 ALDH1A1 (0.39) PLATSLC34A1ALOX5MEN1KMT2A
SCHEMBL10275405 0.88 PLAT (0.46) PLATMAT2ASLC34A1TP53ALOX5
SCHEMBL10275784 0.87 KDM4E (0.40) PLATDHODHKDM4EGAAMAPK14
SCHEMBL10276317 0.86 ALDH1A1 (0.44) PLATSLC34A1ALOX5MEN1KMT2A
SCHEMBL10275451 0.82 MAT2A (0.47) PLATMAT2ADHODHTP53ALOX5
SCHEMBL10313819 0.79 ARF6 (0.44) PLATSLC34A1ALOX5ALDH1A1L3MBTL1
SCHEMBL10276150 0.79 KDM4E (0.42) PLATDHODHMEN1KMT2AALDH1A1
SCHEMBL10313549 0.79 MAPT (0.45) SLC34A1TP53MEN1KMT2AALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20120178915-A1 PYRIMIDINE DERIVATIVES AND ANALOGS, PREPARATION METHOD AND USE THEREOF XU LIFENG (US) 2012-07-12 US claimed
US-20120178915-A1 PYRIMIDINE DERIVATIVES AND ANALOGS, PREPARATION METHOD AND USE THEREOF XU LIFENG (US) 2012-07-12 US disclosed
US-20120178915-A1 PYRIMIDINE DERIVATIVES AND ANALOGS, PREPARATION METHOD AND USE THEREOF XU LIFENG (US) 2012-07-12 US disclosed
WO-2011035518-A1 PYRIMIDINE DERIVATIVES AND ANALOGS, PREPARATION METHOD AND USE THEREOF 辽宁利锋科技开发有限公司 (CN) 2011-03-31 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120178915-A1 PYRIMIDINE DERIVATIVES AND ANALOGS, PREPARATION METHOD AND USE THEREOF TYMP, TYMS, ADORA3 PLAT 2180/4885MAT2A 517/4885DHODH 164/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.